During the past decade, H.U. R. y Cajal conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "H.U. R. y Cajal" are "Gastric Cancer" (1 trials), "Gastroesophageal Junction Cancer" (1 trials) and "Pancreatic Ductal Carcinoma" (1 trials). Many other conditions were trialed in "H.U. R. y Cajal" in a lesser frequency.

Most popular intervention types in "H.U. R. y Cajal" are "Drug" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "BBI608" (1 trials), "Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)" (1 trials), "Gemcitabine" (1 trials) and "Paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "H.U. R. y Cajal" are 2 trials for "All" genders.

Currently, there are NaN active trials in "H.U. R. y Cajal". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in H.U. R. y Cajal, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in H.U. R. y Cajal, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".